ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0138

Evaluating Artificial Intelligence for Diagnosing Antiphospholipid Syndrome in Pulmonary Embolism Case Reports: A Prompt-Based Analysis

Sami Rabah and Xiangyi Kang, Lincoln Medical Center, New York, NY

Meeting: ACR Convergence 2025

Keywords: antiphospholipid syndrome, autoimmune diseases, pulmonary

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0115–0144) Antiphospholipid Syndrome Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Antiphospholipid syndrome (APS) is a complex autoimmune prothrombotic disorder that can present with venous or arterial thromboses, often masquerading as unprovoked pulmonary embolism (PE). The use of artificial intelligence (AI) to assist in diagnostic reasoning is expanding, but its precision in recognizing rare or overlapping disorders like APS remains underexplored.

Methods: We reviewed 958 PubMed entries related to pulmonary embolism and included only English-language case reports with full-text access, adequate clinical detail, and documented APS-related diagnostic testing. Fifty cases met the inclusion criteria. Each case was blinded to the final diagnosis and analyzed using GPT-4 (ChatGPT), which was instructed to list its top three differential diagnoses, assess the likelihood of APS, and indicate whether APS antibody testing was warranted. Final diagnoses were recorded separately for performance assessment.

Results: Among the 50 included cases, 7 had a confirmed diagnosis of APS. ChatGPT correctly identified APS in 4 of 7 cases (sensitivity 57%) and incorrectly suggested APS in 21 non-APS cases (specificity 51%). Overall diagnostic accuracy was 52%, with a positive predictive value (PPV) of 16%, a negative predictive value (NPV) of 88%, and an F1 score of 0.25.ChatGPT also correctly recommended APS antibody testing in all 7 APS cases and withheld testing in 19 of 43 non-APS cases, yielding a testing recommendation sensitivity of 100% and specificity of 44.2%. Additionally, in 73% of all cases, ChatGPT correctly included the final diagnosis—APS or otherwise—within its top three differential diagnoses, demonstrating consistent clinical reasoning across a wide range of thrombotic etiologies including hereditary thrombophilia, malignancy, infection, and anatomical anomalies. Performance by diagnosis category is summarized in Figure 1, and APS classification performance is illustrated in the confusion matrix (Figure 2).

Conclusion: ChatGPT-4 demonstrates potential in supporting differential diagnosis generation in complex PE cases. While it overcalls APS in some instances, it consistently identifies relevant thrombotic mechanisms and reliably flags cases warranting APS testing. These findings support the growing role of artificial intelligence in complex diagnostic workflows and highlight the importance of structured prompt design in enhancing model accuracy and clinical relevance.

Supporting image 1Bar chart showing the percentage of cases in which ChatGPT correctly included the final diagnosis category within its top three differentials. Categories include APS, malignancy, hereditary thrombophilia, anatomical anomalies, COVID-related thrombosis, autoimmune (non-APS), and other causes.

Supporting image 2Heatmap illustrating true positives, false positives, true negatives, and false negatives based on whether ChatGPT suggested APS in each case. The matrix is based on 50 PE case reports, 7 of which were confirmed to be APS.


Disclosures: S. Rabah: None; X. Kang: None.

To cite this abstract in AMA style:

Rabah S, Kang X. Evaluating Artificial Intelligence for Diagnosing Antiphospholipid Syndrome in Pulmonary Embolism Case Reports: A Prompt-Based Analysis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/evaluating-artificial-intelligence-for-diagnosing-antiphospholipid-syndrome-in-pulmonary-embolism-case-reports-a-prompt-based-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluating-artificial-intelligence-for-diagnosing-antiphospholipid-syndrome-in-pulmonary-embolism-case-reports-a-prompt-based-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology